Credits Available: 4.75 hours of AMA PRA Category 1 Credit™, ANCC, and ACPE. MOC Points Available

Description: Endometrial cancer is among the few cancers increasing in incidence and mortality in the United States. In its early stages, endometrial carcinoma has a five-year relative survival rate of 96%, but it decreases to 18% for those with metastases. Surprisingly, mortality has been increasing faster than incidence. This is attributed to increasing rates of advanced cancers, higher-risk histologies, and older age of first diagnosis. Yet, there have also been increases in diagnoses in women aged less than 50 years, based on Surveillance, Epidemiology, and End Results (SEER) program data.

While the incidence and mortality has been increasing across all racial groups, the rate of increase for Black women has been the steepest. Adjusting for the higher rate of hysterectomy in Black women compared with White women, the differing rates of this cancer in these groups exemplify this racial disparity.

These statistics demonstrate the need for new therapeutics and subsequent education on their use in this field. To improve clinical outcomes, clinicians treating patients for advanced/recurrent endometrial cancer need to understand biomarker testing and molecular classification of disease, newest guidelines on management, and the evidence underlying these recommendations. Along with this, clinicians must be aware of the most effective ways to manage possible adverse events. To these ends, this educational initiative will allow clinicians managing patients with advanced/recurrent endometrial cancer to learn and discuss the crucial points in diagnosing and managing these patients to best increase long-term survival.

Montefiore Einstein Logo

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Pharmacist, Nurse
Target Specialties: Gynecologic Oncology, Oncology

Abigail Shockley

MD Anderson Cancer Center
Clinical Pharmacy Specialist

Dr. Abigail Shockley is a professional in the field of pharmacy, specializing in breast medical oncology. Dr. Abigail Shockley obtained a Doctor of Pharmacy (Pharm.D.) degree from Purdue University. Following graduation, Dr. Shockley pursued a PGY1 General Residency at MUSC Health (Medical University of South Carolina) in order to broaden her clinical knowledge and skills. Driven by a passion for oncology, Dr. Shockley further specialized by completing a PGY2 Oncology Residency at MUSC Health Hollings Cancer Center.
With a solid foundation in oncology pharmacy, Dr. Abigail Shockley is currently based at MD Anderson Cancer Center, one of the world's most renowned cancer treatment centers, Dr. Shockley plays a pivotal role in the multidisciplinary care team.
As a specialist in breast medical oncology, Dr. Shockley leverages her in-depth knowledge of oncology medications, treatment guidelines, and emerging therapies to optimize treatment plans for patients with breast cancer. She collaborates closely with oncologists, nurses, and other healthcare professionals to ensure the delivery of the most effective and personalized care.